An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men diagnosed with prostate cancer (≥1 claim for prostate cancer).
Treatment with apalutamide, darolutamide or enzalutamide initiated for the first time in the nmPC stage during the patient identification period.
Age ≥ 18 years at index date
At least 6 months of continuous eligibility in medical and pharmacy benefits prior to the index date
At least 6-months of continuous eligibility only in pharmacy benefits after the index date unless patient died before 6 months.
You may not be if
Patients with multiple ARIs recorded at index date
Use of an ARI agent or abiraterone acetate prior to the index date
Other cancer diagnosis (except prostate and skin cancer) during the 6-month baseline period
Evidence of metastatic disease any time before or 30 days after index date.
No claim with a diagnosis for hormone sensitive malignancy status (Z19.1) during the study period
Clareo Health | An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
